Reported Earlier, ImmuCell Preliminary Q4 Sales Of $7.8M (+52% YoY) and Fiscal 2024 Of $26.5M (+52% YoY), Driven by Increased Production
Author: Benzinga Newsdesk | January 10, 2025 03:21am
Preliminary, Unaudited Total Sales Results:
2024
2023
$ Increase
% Increase
During the Three-Month Periods Ended December 31,
$7.8 million
$5.1 million
$2.7 million
52%
During the Years Ended December 31,
$26.5 million
$17.5 million
$9.0 million
52%
During the three-month period ended December 31, 2024, annualized production output was approximately 103% of the Company's estimated full capacity of approximately $30 million per year. This production output helped reduce the backlog of orders to approximately $4.4 million as of January 1, 2025 from approximately $9.4 million as of January 1, 2024. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of peak calving season during the first quarter.
